Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 9
---
 and (Z) such time, from and after the Additional VWAP Purchase Commencement Time for such Additional
VWAP Purchase, that the Sale Price has fallen below the applicable Additional VWAP Purchase Minimum Price Threshold (such earliest of
(X), (Y) and (Z) above, the “”). Notwithstanding the foregoing, in the event
that (a) the Investor is the holder of any Depositary Shares on the Additional VWAP Purchase Date that were the subject of an Additional
VWAP Purchase Notice for such Additional VWAP Purchase Date, and (b) if within three (3) Business Days following an Additional VWAP Purchase
Date, the Company issues or sells any Depositary Shares or Ordinary Share Equivalents (calculated on an as converted, as exercised basis),
in each case other than pursuant to an Exempt Issuance, pursuant to which Depositary Shares may be acquired at a New Issuance Price, then
at the option of the Investor, the Additional VWAP Purchase Price related to that subject Additional VWAP Purchase Notice may be reduced
to the New Issuance Price, subject to hereof.

(e) “” means, with respect to an Additional VWAP Purchase made pursuant to hereof,
the number of Purchase Shares directed by the Company to be purchased by the Investor on an Additional VWAP Purchase Notice, which number
of Purchase Shares shall not exceed $2,500,000 of Purchase Shares.

(f) “” means, with respect to an Additional VWAP Purchase made pursuant to hereof,
thirty percent (30%).

(g) “” means, with respect to an Additional VWAP Purchase made pursuant to
hereof, a number of Depositary Shares equal to (i) the number of Purchase Shares specified by the Company in the applicable Additional
VWAP Purchase Notice as the Additional VWAP Purchase Share Amount to be purchased by the Investor in such Additional VWAP Purchase, divided
by (ii) the Additional VWAP Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, share split, reverse share split, Depositary Share-Ordinary Share ratio change or other similar transaction).

(h) “” means, initially, Thirty-Five Million Dollars ($35,000,000) in the aggregate, which amount shall be reduced by the Purchase
Amount each time the Investor purchases Purchase Shares pursuant to hereof.

(i) “” means Title 11, U.S. Code, or any similar